VIPAS39 confers ferroptosis resistance in epithelial ovarian cancer through exporting ACSL4
Funded by Beijing Municipal Natural Science Foundation (Key program Z220011), National Natural Science Foundation of China (NSFC) (T2225006, T2488301, 82272948), Peking University Medicine Youth Science and Technology Innovation 'Sail Plan' Project Type B Medical Interdisciplinary Seed Fund (71006Y3171), GuangDong Basic and Applied Basic Research Foundation (2021A1515110820), and the special fund of the National Clinical Key Speciality Construction Program, P. R. China (2023).
Authors
- Wei Yue (ORCID: https://orcid.org/0000-0003-1399-5070)
- Mo Li (ORCID: https://orcid.org/0000-0001-7005-7545)
- Yuening Jiang
- Tianzhen Wang (ORCID: https://orcid.org/0000-0002-7525-8466)
- Xinyu Li (ORCID: https://orcid.org/0000-0002-0424-2766)
- Jie Li (ORCID: https://orcid.org/0000-0002-4433-5393)
- Xiaoyang Gu (ORCID: https://orcid.org/0009-0001-9187-0276)
- Zhaofei Liu (ORCID: https://orcid.org/0000-0003-4556-6641)
Institutions
- Hebei North University (CN)
- Bengbu Medical College (CN)
- Peking University (CN)
- Peking University Third Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- EBioMedicine
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1016/j.ebiom.2025.105646
- Citations
- 3
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 4.56